Evidence map›Paper›PMID 32050900›Full record

Observational studyBMC medical research methodology2020

Comparison of retention in observational cohorts and nested simulated HIV vaccine efficacy trials in the key populations in Uganda.

Andrew Abaasa, Jim Todd, Stephen Nash, Yunia Mayanja, Pontiano Kaleebu, Patricia E Fast, Matt Price

Open access · goldAbstract readComparative StudyObservational Study
In one paragraph

Observational study in BMC medical research methodology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Observational
  3. Predictors of Loss to Follow-Up in an HIV Vaccine Preparedness Study in Masaka, Uganda.International journal of environmental research and public health · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 3 countries.

Andrew AbaasaMRC/UVRI & LSHTM Uganda Research Unit, Entebbe, Uganda. Andrew.Abaasa@mrcuganda.org.
Jim ToddLondon School of Hygiene and Tropical Medicine, London, UK.
Stephen NashLondon School of Hygiene and Tropical Medicine, London, UK.
Yunia MayanjaMRC/UVRI & LSHTM Uganda Research Unit, Entebbe, Uganda.
Pontiano KaleebuMRC/UVRI & LSHTM Uganda Research Unit, Entebbe, Uganda.
Patricia E FastInternational AIDS Vaccine Initiative, New York, USA.
Matt PriceInternational AIDS Vaccine Initiative, New York, USA.
Uganda Virus Research Institute · UGLondon School of Hygiene & Tropical Medicine · GBInternational AIDS Vaccine Initiative · USStanford University · US

Funding

Medical Research Council
6 · The paper itself

Abstract

backgroundOutcomes in observational studies may not best estimate those expected in the HIV vaccine efficacy trials. We compared retention in Simulated HIV Vaccine Efficacy Trials (SiVETs) and observational cohorts drawn from two key populations in Uganda.

methodsTwo SiVETs were nested within two observational cohorts, one in Fisherfolk (FF) and another one in Female Sex Workers (FSW). Adult participants in each observational cohort were screened for enrolment into SiVETs. Those screened-out or not screened continued participation in the observational (non-SiVET) cohorts. SiVET participants were administered a licensed hepatitis B vaccine in a schedule that mimicked an actual HIV vaccine efficacy trial. Both cohorts were followed for 12 months and retention was assessed through dropout, defined as lost to follow up, being uncontactable, refusal to continue or missing the last study clinic visit. Dropout rates were compared using Poisson models giving rate ratios and 95% confidence intervals (95%CI).

resultsOut of 1525 participants (565 FF and 960 FSW), 572 (38%) were enrolled into SiVETs (282-FF and 290-FSW), and 953 (62%) remained in the non-SiVET cohorts. Overall, 326 (101 SiVET, 225 non-SiVET) dropped out in 1260 Person Years of Observation (PYO), a dropout rate of 25.9 /100 PYO (95%CI: 23.2-28.8); fewer dropped out in the SiVET cohorts (18.4, 95% CI: 15.1-22.4) than in the non-SiVET cohorts (31.6, 95% CI: 27.8-36.1), rate ratio (RR) =0.58, 95% CI: 0.46-0.73. In all cohorts, the dropout was more marked in FSW than in FF population. Duration lived in community was associated with dropout in both SiVETs and religion in both non-SiVET cohorts.

conclusionThe rate of dropout was lower in SiVET compared to non-SiVET cohort. Though the difference in dropout between SiVET and non-SiVET was generally similar, the actual dropout rates were higher in the FSW population. Conduct of SiVETs in these key populations could mean that designing HIV Vaccine Efficacy Trials will benefit from lower dropout rate shown in SiVET than non-SiVET observational cohort.

Indexed as

AdolescentAdultAIDS VaccinesCohort StudiesFemaleFisheriesHIV InfectionsHumansIncidenceMaleMass ScreeningSex WorkersTreatment OutcomeUgandaYoung AdultAIDS VaccinesRetention dropout observational cohorts vaccine trials key-populations

Identifiers

PMID32050900
PMCPMC7014936
OpenAlexW3009786784

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.